Clinical Trials Logo

Renal Insufficiency clinical trials

View clinical trials related to Renal Insufficiency.

Filter by:

NCT ID: NCT00071214 Completed - Clinical trials for Kidney Failure, Chronic

Study to Evaluate the Effectiveness of StaphVAX in Adults on Hemodialysis

Start date: September 2003
Phase: Phase 3
Study type: Interventional

Two part study testing the effectiveness and safety of StaphVAX vaccine in chronic hemodialysis patients against infection by Staphylococcus aureus.

NCT ID: NCT00069810 Withdrawn - Clinical trials for Cardiovascular Diseases

Role of Chronic Kidney Disease in Cardiovascular Disease

Start date: August 2003
Phase: N/A
Study type: Observational

The purpose of this study is to determine how the progressive loss of kidney function influences cardiovascular disease.

NCT ID: NCT00067119 Completed - Kidney Failure Clinical Trials

Aggrenox Prevention of Access Stenosis

GRAFT
Start date: January 1, 2003
Phase: Phase 3
Study type: Interventional

The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs primary unassisted patency in newly created arteriovenous grafts. This record previously included information for both the GRAFT and FISTULA trials.

NCT ID: NCT00062621 Completed - Multiple Myeloma Clinical Trials

Combined Bone Marrow and Kidney Transplant for Multiple Myeloma With Kidney Failure

Start date: June 2003
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether a combined bone marrow and kidney transplant will be effective in treating stage II or greater multiple myeloma and associated kidney failure. This study will determine whether transplant rejection and the need for immunosuppressive drugs are decreased with this combined transplant approach.

NCT ID: NCT00049907 Completed - Hypertension Clinical Trials

Cardiac and Renal Disease Study (CARDS)

Start date: September 2002
Phase: N/A
Study type: Observational

To examine the epidemiology of renal disease and its relationship to cardiovascular disease.

NCT ID: NCT00048516 Completed - Clinical trials for Renal Insufficiency, Chronic

Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Daily Dosing)

Start date: February 2002
Phase: Phase 3
Study type: Interventional

The objective of this study is to determine whether paricalcitol is safe and effective compared to placebo in reducing elevated serum PTH levels in patients with chronic kidney disease.

NCT ID: NCT00048451 Completed - Clinical trials for Renal Insufficiency, Chronic

Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)

Start date: February 2002
Phase: Phase 3
Study type: Interventional

The objective of this study is to determine whether paricalcitol is safe and effective compared to placebo in reducing elevated serum PTH levels in patients with chronic kidney disease.

NCT ID: NCT00048438 Completed - Clinical trials for Renal Insufficiency, Chronic

Safety and Efficacy of Zemplar Capsule in Reducing Serum IPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)

Start date: February 2002
Phase: Phase 3
Study type: Interventional

The objective of this study is to determine whether paricalcitol is safe and effective compared to placebo in reducing elevated serum PTH levels in patients with chronic kidney disease.

NCT ID: NCT00044720 Completed - Clinical trials for Kidney Transplantation

Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients

Start date: n/a
Phase: Phase 4
Study type: Interventional

The incidence of efficacy failure at 12 months between two regimens.

NCT ID: NCT00042432 Completed - Clinical trials for Secondary Hyperparathyroidism

Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients

Start date: June 2002
Phase: Phase 2
Study type: Interventional

This study will assess an investigational medication for patients with chronic renal insufficiency (pre-dialysis) who have secondary hyperparathyroidism.